Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Profit After Tax (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Profit After Tax data on record, last reported at -$2.1 million in Q4 2025.

  • For Q4 2025, Profit After Tax rose 19.49% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$7.7 million, up 2.88%, while the annual FY2025 figure was -$8.2 million, 6.0% down from the prior year.
  • Profit After Tax reached -$2.1 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$300000.0 in Q2 2023 and bottomed at -$7.9 million in Q2 2022.
  • Average Profit After Tax over 5 years is -$2.6 million, with a median of -$2.1 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: skyrocketed 96.19% in 2023, then crashed 554.04% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$4.3 million in 2021, then surged by 50.94% to -$2.1 million in 2022, then grew by 29.65% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then rose by 19.49% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$2.1 million in Q4 2025, -$1.7 million in Q3 2025, and -$1.8 million in Q2 2025.